Storia in 3 fonti

First-in-Class Drug Approved for IgA Nephropathy

It has not been established whether atacicept slows kidney function decline long-term, however

Raccontata da

healio.com

medpagetoday.com

fiercepharma.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo3 g fa

First-in-Class Drug Approved for IgA Nephropathy

It has not been established whether atacicept slows kidney function decline long-term, however

originale

healio.com4 g fa

FDA approves Trutakna for proteinuria reduction in IgA nephropathy

The FDA granted accelerated approval to atacicept-vymj for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to an agency press release. Atacicept-vymj…

Leggi questa versione → originale

Timeline cronologica

martedì 7 luglio 2026·healio.com
FDA approves Trutakna for proteinuria reduction in IgA nephropathy
The FDA granted accelerated approval to atacicept-vymj for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to…
martedì 7 luglio 2026·medpagetoday.com
First-in-Class Drug Approved for IgA Nephropathy
It has not been established whether atacicept slows kidney function decline long-term, however

First-in-Class Drug Approved for IgA Nephropathy

Confronto fonti

First-in-Class Drug Approved for IgA Nephropathy

FDA approves Trutakna for proteinuria reduction in IgA nephropathy

Timeline cronologica

FDA approves Trutakna for proteinuria reduction in IgA nephropathy

First-in-Class Drug Approved for IgA Nephropathy

FDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsuka

FDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsuka